Updates of prostate cancer staging: Prostate-specific membrane antigen - Wikidata - wikimedia - TriplyDB

Updates of prostate cancer staging: Prostate-specific membrane antigen

Updates of prostate cancer staging: Prostate-specific membrane antigen

http://www.wikidata.org/entity/Q28079444

about

99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.

P2860

Q47438555-1F62FAB8-D201-46A5-A5AB-6F6F2FC9154C

P2860

Updates of prostate cancer staging: Prostate-specific membrane antigen

http://www.wikidata.org/entity/Q28079444

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Updates of prostate cancer staging: Prostate-specific membrane antigen

@ast

Updates of prostate cancer staging: Prostate-specific membrane antigen

@en

Updates of prostate cancer staging: Prostate-specific membrane antigen

@nl

type

label

Updates of prostate cancer staging: Prostate-specific membrane antigen

@ast

Updates of prostate cancer staging: Prostate-specific membrane antigen

@en

Updates of prostate cancer staging: Prostate-specific membrane antigen

@nl

prefLabel

Updates of prostate cancer staging: Prostate-specific membrane antigen

@ast

Updates of prostate cancer staging: Prostate-specific membrane antigen

@en

Updates of prostate cancer staging: Prostate-specific membrane antigen

@nl

P1433

Q28079444-BB666214-DADC-43A5-A001-D4452D21AD47

P1476

Q28079444-D408BF2A-2555-4520-A117-058321C87C18

P2093

Q28079444-17C85E9F-DE74-40B0-BCE0-233C99B42453

Q28079444-619A50A0-57BF-434D-856F-F76D290DE980

Q28079444-71909B55-3810-4B78-AB54-8068DF03EFE6

Q28079444-7DDE1433-3619-4768-857D-7F8191D78183

Q28079444-8CE54A94-C526-4E0A-8B66-9849501593A7

Q28079444-D681D35E-B6FD-415D-881C-5742C5D4DEF7

Q28079444-D73029D8-9745-4D24-A80B-99A7FDD2A811

P2860

Q28079444-00350224-BDA4-419F-8155-939997A01B0A

Q28079444-06777BFF-4E86-49EB-8AE4-EF8FAB25912B

Q28079444-1361BB8F-B93B-482D-A7EC-0BDC264FA1E0

Q28079444-1F8A3183-E63B-4BFD-B7C3-8B2A1C01694E

Q28079444-20611F7B-790B-4696-A2B6-4E4C6EB77660

Q28079444-2FE4450C-1263-41D5-B756-A9DF48834454

Q28079444-38DDE62A-85C5-4A75-846A-CBB3B668B85A

Q28079444-4E6E761C-ADFD-471F-876A-8DFD2CE3452B

Q28079444-588F0378-979C-4C4C-8BA7-37AC9C64C81C

Q28079444-5FF19E85-7A61-4454-977B-2A3DB71941C6

P304

Q28079444-E252B34F-6D26-4BA6-8C30-6D4DB0C21DDA

P31

Q28079444-6675462C-0723-4F62-93A8-597345068B93

P356

Q28079444-E5377CA5-3B81-4A82-B4EF-ACD67A544ECE

P407

Q28079444-D025FE9F-AB87-444F-9985-34E8670044A1

P433

Q28079444-725FEC1F-5495-46CE-8821-610D05A40F9F

P478

Q28079444-FAB75696-DA9B-40FF-B9CD-BAFACA83354A

P50

Q28079444-13331E61-13B1-422D-9379-E916F34153F5

P577

Q28079444-543CBFC9-122F-4E44-BE12-C9AEDFBA55F5

P698

Q28079444-A3F93953-2D38-4825-A8C9-02D7E701ABCD

P932

Q28079444-274B9ED0-28F5-4058-A4B1-6AA92299FD07

P356

ICU.2016.57.S2.S147

P1433

Investigative and clinical urology

P1476

Updates of prostate cancer staging: Prostate-specific membrane antigen

@en

P2093

Alastair Lamb

http://www.w3.org/2001/XMLSchema#string

Catherine Mitchell

http://www.w3.org/2001/XMLSchema#string

Daniel A Moon

http://www.w3.org/2001/XMLSchema#string

Declan G Murphy

http://www.w3.org/2001/XMLSchema#string

Nathan L Lawrentschuk

http://www.w3.org/2001/XMLSchema#string

Nicolas Geurts

http://www.w3.org/2001/XMLSchema#string

Rajesh Nair

http://www.w3.org/2001/XMLSchema#string

P2860

Prostate-specific membrane antigen as a target for cancer imaging and therapy

Cancer statistics, 2015

Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

Natural history of progression after PSA elevation following radical prostatectomy.

Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

P304

S147-S154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4111/ICU.2016.57.S2.S147

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Niranjan J Sathianathen

P577

2016-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27995218

http://www.w3.org/2001/XMLSchema#string

P932

5161015

http://www.w3.org/2001/XMLSchema#string